Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04775485




Registration number
NCT04775485
Ethics application status
Date submitted
3/02/2021
Date registered
1/03/2021
Date last updated
27/12/2023

Titles & IDs
Public title
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Scientific title
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
Secondary ID [1] 0 0
DAY101-001/PNOC026
Universal Trial Number (UTN)
Trial acronym
FIREFLY-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Low-grade Glioma 0 0
Advanced Solid Tumor 0 0
Condition category
Condition code
Cancer 0 0 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - DAY101

Experimental: Arm #1 - Pediatric patients with low-grade glioma treated with DAY101 (Registrational Arm)

Experimental: Arm #2 - Expanded access arm of pediatric patients with low-grade glioma treated with DAY101

Experimental: Arm #3 - Pediatric patients with advanced solid tumors treated with DAY101


Treatment: Drugs: DAY101
DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Arm 1: Overall response rate (ORR) by independent radiology review committee (IRC) based on RANO criteria
Timepoint [1] 0 0
Up to 48 months
Primary outcome [2] 0 0
Arm 2: Assess the safety and tolerability of DAY101
Timepoint [2] 0 0
Up to 48 months
Primary outcome [3] 0 0
Arm 3: Overall response rate (ORR) by independent radiology review committee (IRC) based on RECIST v1.1 criteria
Timepoint [3] 0 0
Up to 48 months
Secondary outcome [1] 0 0
Relationship between pharmacokinetics (PK) and drug effects
Timepoint [1] 0 0
Up to 48 months
Secondary outcome [2] 0 0
Effect on electrocardiogram (ECG) and QT interval corrected for heart rate by Fridericia's formula (QTcF) prolongation
Timepoint [2] 0 0
Up to 48 months
Secondary outcome [3] 0 0
ORR by Investigator
Timepoint [3] 0 0
Up to 48 months
Secondary outcome [4] 0 0
Evaluate the concordance of prior local laboratory BRAF molecular profiling with a central BRAF alteration assay being evaluated by the Sponsor
Timepoint [4] 0 0
Up to 48 months
Secondary outcome [5] 0 0
Arm 1: Evaluate visual acuity (VA) outcomes compared with baseline
Timepoint [5] 0 0
Up to 48 months
Secondary outcome [6] 0 0
Arms 1 & 2: ORR by IRC and Investigator using RAPNO criteria
Timepoint [6] 0 0
Up to 48 months
Secondary outcome [7] 0 0
Arms 1 & 2: Progression free survival (PFS) using RANO and RAPNO criteria by 1) an IRC and 2) the treating Investigator (RANO only)
Timepoint [7] 0 0
Up to 48 months
Secondary outcome [8] 0 0
Arms 1 & 2: Duration of response (DOR) with best overall response of CR or PR using RANO and RAPNO criteria by 1) an IRC and 2) the treating Investigator (RANO only)
Timepoint [8] 0 0
Up to 48 months
Secondary outcome [9] 0 0
Arms 1 & 2: Time to response following initiation of DAY101
Timepoint [9] 0 0
Up to 48 months
Secondary outcome [10] 0 0
Arms 1 & 2: Clinical benefit rate based on the proportion of patients with best overall response using RANO or RAPNO criteria
Timepoint [10] 0 0
Up to 48 months
Secondary outcome [11] 0 0
Arms 1 & 3: Assess the safety and tolerability of DAY101
Timepoint [11] 0 0
Up to 48 months
Secondary outcome [12] 0 0
Arm 3: Duration of response (DOR) with best overall response of CR or PR using RECIST v1.1 criteria by 1) an IRC and 2) the treating Investigator
Timepoint [12] 0 0
Up to 48 months
Secondary outcome [13] 0 0
Arm 3: Time to response following initiation of DAY101
Timepoint [13] 0 0
Up to 48 months
Secondary outcome [14] 0 0
Arm 3: Clinical benefit rate based on the proportion of patients with best overall response using RECIST v1.1 criteria
Timepoint [14] 0 0
Up to 48 months

Eligibility
Key inclusion criteria
* Age 6 months to 25 years with:

1. Arms 1 & 2: a relapsed or progressive LGG with documented known activating BRAF alteration
2. Arm 3: locally advanced or metastatic solid tumor with documented known or expected to be activating RAF fusion
* Confirmation of histopathologic diagnosis of LGG and molecular diagnosis of activating BRAF alteration
* Must have received at least one line of systemic therapy and have evidence of radiographic progression
* Must have at least 1 measurable lesion as defined by RANO (Arms 1 & 2) or RECIST v1.1 (Arm 3) criteria
Minimum age
6 Months
Maximum age
25 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patient's tumor has additional previously-known activating molecular alterations
* Patient has symptoms of clinical progression in the absence of radiographic progression
* Known or suspected diagnosis of neurofibromatosis type 1 (NF-1)
* Other inclusion/exclusion criteria as stipulated by protocol may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
10/06/2024
Actual
Sample size
Target
140
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Queensland Children's Hospital - Brisbane
Recruitment hospital [2] 0 0
Royal Children's Hospital - Parkville
Recruitment hospital [3] 0 0
Perth Children's Hospital - Perth
Recruitment hospital [4] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [5] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 0 0
4101 - Brisbane
Recruitment postcode(s) [2] 0 0
3052 - Parkville
Recruitment postcode(s) [3] 0 0
WA 6009 - Perth
Recruitment postcode(s) [4] 0 0
NSW 2031 - Randwick
Recruitment postcode(s) [5] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Maryland
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Canada
State/province [15] 0 0
Quebec
Country [16] 0 0
Denmark
State/province [16] 0 0
Copenhagen
Country [17] 0 0
Germany
State/province [17] 0 0
Berlin
Country [18] 0 0
Germany
State/province [18] 0 0
Heidelberg
Country [19] 0 0
Israel
State/province [19] 0 0
Haifa
Country [20] 0 0
Israel
State/province [20] 0 0
Petah Tikva
Country [21] 0 0
Israel
State/province [21] 0 0
Ramat Gan
Country [22] 0 0
Korea, Republic of
State/province [22] 0 0
Seoul
Country [23] 0 0
Netherlands
State/province [23] 0 0
Utrecht
Country [24] 0 0
Singapore
State/province [24] 0 0
Singapore
Country [25] 0 0
Switzerland
State/province [25] 0 0
Zürich
Country [26] 0 0
United Kingdom
State/province [26] 0 0
London
Country [27] 0 0
United Kingdom
State/province [27] 0 0
Newcastle Upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Day One Biopharmaceuticals, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Pacific Pediatric Neuro-Oncology Consortium
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Trial website
https://clinicaltrials.gov/study/NCT04775485
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Day One Biopharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
650-484-0899
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04775485